Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Goodwill & Intangibles (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Goodwill & Intangibles for 4 consecutive years, with $6.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Goodwill & Intangibles fell 12.15% to $6.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.2 million, a 12.15% decrease, with the full-year FY2024 number at $6.2 million, down 12.15% from a year prior.
  • Goodwill & Intangibles was $6.2 million for Q4 2024 at Rhythm Pharmaceuticals, down from $6.6 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $7.9 million in Q4 2022 to a low of $4.7 million in Q4 2021.
  • A 4-year average of $6.2 million and a median of $6.4 million in 2024 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: skyrocketed 69.24% in 2022, then fell 12.15% in 2024.
  • Rhythm Pharmaceuticals' Goodwill & Intangibles stood at $4.7 million in 2021, then surged by 69.24% to $7.9 million in 2022, then fell by 10.85% to $7.0 million in 2023, then dropped by 12.15% to $6.2 million in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Goodwill & Intangibles are $6.2 million (Q4 2024), $6.6 million (Q2 2024), and $7.0 million (Q4 2023).